Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh

Results from a Chinese Phase III study focused on diabetes regulation were presented as a late-breaking abstract at the European Association for the Study of Diabetes (EASD) annual meeting in Milan, held September 28 to October 2, 2026. The provided article excerpt does not disclose the study drug, efficacy or safety outcomes, patient population, or financial implications, limiting assessment of the clinical and market significance.